BioXcel Therapeutics Enhances Leadership with Appointment of Chetan D. Lathia, Ph.D. as Senior Vice President, and Head of Tr...
September 18 2018 - 8:00AM
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage
biopharmaceutical development company utilizing novel artificial
intelligence (“AI”) approaches to identify the next wave of
medicines across neuroscience and immuno-oncology, today announced
the appointment of Dr. Chetan D. Lathia as Senior Vice President
and Head, Translational Medicine, Clinical Pharmacology and
Regulatory Affairs; effective immediately.
Dr. Vimal Mehta, Founder and Chief Executive
Officer of BTI, commented, “Over the last several months, we have
developed our corporate infrastructure through a number of key
strategic hires, and we are pleased that Dr. Lathia has joined BTI.
He has over 28 years of experience in clinical pharmacology,
nonclinical development, and regulatory affairs at both large and
small biopharma companies. He has made an immediate impact in
shaping and implementing the regulatory strategy for our lead
clinical programs and has begun evaluating our emerging preclinical
candidates.”
“By combining AI and drug development expertise in
neuroscience and oncology, BioXcel Therapeutics has significant
potential to accelerate the development of promising drug
candidates to improve clinical outcomes for patients,” said Dr.
Lathia. “I am very excited to be working with the BTI team. I look
forward to leading nonclinical development, clinical pharmacology,
regulatory strategy & global regulatory interactions that
support our two lead clinical programs as well as the product
pipeline.”
Dr. Lathia has co-led the IND submissions for a
number of new molecular entities and eight new drug applications
(NDA) / biologics license application (BLA) in the US, Europe,
Japan, China, etc. In addition to presenting clinical pharmacology
& clinical strategy at meetings with drug regulators, he has
made presentations to the Special Advisory Group (SAG) of the
European Medicines Agency and an advisory meeting held by Taiwanese
regulators. Dr. Lathia has delivered presentations to the Food
and Drug Administration on invitation from the agency's Office of
Clinical Pharmacology.
Most recently, Dr. Lathia served as the VP and Head
of Clinical Pharmacology at Intarcia Therapeutics where he was
responsible for leading the pharmacokinetics (PK)/pharmacodynamics
(PD), immunogenicity and bioanalytical strategy. Prior to that, Dr.
Lathia served as the Executive Director, Clinical Pharmacology at
Alexion Pharmaceuticals where he led the global clinical and
nonclinical PK/PD, pharmacometrics, and bioanalytics functions.
Previously, Dr. Lathia served as the Global Head, Oncology
Biomarkers and Pharmacokinetics and as the Global Clinical
Pharmacology Leader for Nexavar at Bayer. Prior to this he was a
Senior Research Associate at Parke-Davis Research where he co-led
drug metabolism, nonclinical & clinical PK functions for the
oncology & cardiovascular portfolio.
Dr. Lathia earned a doctorate in pharmacokinetics
from Virginia Commonwealth University and a bachelor’s in pharmacy,
with a gold medal in pharmacology from L M College of Pharmacy,
India.
About BioXcel Therapeutics,
Inc.:BioXcel Therapeutics, Inc. is a clinical stage
biopharmaceutical company focused on drug development that utilizes
novel artificial intelligence approaches to identify the next wave
of medicines across neuroscience and immuno-oncology. The Company's
drug re-innovation approach leverages existing approved drugs
and/or clinically validated product candidates together with big
data and proprietary machine learning algorithms to identify new
therapeutic indices. The Company's two most advanced clinical
development programs are BXCL501, a sublingual thin film
formulation designed for acute treatment of agitation resulting
from neurological and psychiatric disorders, and BXCL701, an
immuno-oncology agent designed for treatment of a rare form of
prostate cancer and for treatment of pancreatic cancer. For more
information, please visit www.bioxceltherapeutics.com.
Forward-Looking StatementsThis
press release includes “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release include, but are
not limited to, statements that relate to the advancement and
development of BXCL701, the commencement of clinical trials, the
availability of data from clinical trials and other information
that is not historical information. When used herein, words such as
“anticipate”, “being”, “will”, “plan”, “may”, “continue”, and
similar expressions are intended to identify forward-looking
statements. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon
BioXcel’s current expectations and various assumptions. BioXcel
believes there is a reasonable basis for its expectations and
beliefs, but they are inherently uncertain. BioXcel may not realize
its expectations, and its beliefs may not prove correct. Actual
results could differ materially from those described or implied by
such forward-looking statements as a result of various important
factors, including, without limitation, market conditions and the
factors described under the caption “Risk Factors” in BioXcel’s 10
Q for the Quarter ended June 30, 2018 and BioXcel’s other filings
made with the Securities and Exchange Commission. Consequently,
forward-looking statements should be regarded solely as BioXcel’s
current plans, estimates and beliefs. Investors should not place
undue reliance on forward-looking statements. BioXcel cannot
guarantee future results, events, levels of activity, performance
or achievements. BioXcel does not undertake and specifically
declines any obligation to update, republish, or revise any
forward-looking statements to reflect new information, future
events or circumstances or to reflect the occurrences of
unanticipated events, except as may be required by law.
Contact Information:The Ruth
GroupLee Roth / Janhavi Mohite646-536-7012 /
7026lroth@theruthgroup.com / jmohite@theruthgroup.com
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Apr 2023 to Apr 2024